-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Corticosteroid -X- _ B-Intervention
treatment -X- _ I-Intervention
has -X- _ O
been -X- _ O
widely -X- _ O
used -X- _ O
in -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
septic -X- _ O
shock -X- _ O
, -X- _ O
influenza -X- _ O
, -X- _ O
and -X- _ O
ARDS -X- _ O
, -X- _ O
although -X- _ O
some -X- _ O
previous -X- _ O
studies -X- _ O
discourage -X- _ O
its -X- _ O
use -X- _ O
in -X- _ O
severe -X- _ O
influenza -X- _ O
patients. -X- _ O
This -X- _ O
multicenter -X- _ O
retrospective -X- _ O
cohort -X- _ O
study -X- _ O
conducted -X- _ O
in -X- _ O
the -X- _ O
intensive -X- _ O
care -X- _ O
units -X- _ O
( -X- _ O
ICUs -X- _ O
) -X- _ O
of -X- _ O
eight -X- _ O
medical -X- _ O
centers -X- _ O
across -X- _ O
Taiwan -X- _ O
aims -X- _ O
to -X- _ O
determine -X- _ O
the -X- _ O
real-world -X- _ O
status -X- _ O
of -X- _ O
corticosteroid -X- _ B-Intervention
treatment -X- _ I-Intervention
in -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
influenza-associated -X- _ I-Patient
acute -X- _ I-Patient
respiratory -X- _ I-Patient
distress -X- _ I-Patient
syndrome -X- _ I-Patient
( -X- _ I-Patient
ARDS -X- _ I-Patient
) -X- _ I-Patient
and -X- _ O
its -X- _ O
impact -X- _ O
on -X- _ O
clinical -X- _ O
outcomes. -X- _ O
Between -X- _ O
October -X- _ O
2015 -X- _ O
and -X- _ O
March -X- _ O
2016 -X- _ O
, -X- _ O
consecutive -X- _ O
ICU -X- _ O
patients -X- _ O
with -X- _ O
virology-proven -X- _ O
influenza -X- _ O
infections -X- _ O
who -X- _ O
fulfilled -X- _ O
ARDS -X- _ O
and -X- _ O
received -X- _ O
invasive -X- _ O
mechanical -X- _ O
ventilation -X- _ O
were -X- _ O
enrolled. -X- _ O
The -X- _ O
impact -X- _ O
of -X- _ O
early -X- _ O
corticosteroid -X- _ B-Intervention
treatment -X- _ I-Intervention
( -X- _ I-Intervention
≥ -X- _ I-Intervention
200 -X- _ I-Intervention
mg -X- _ I-Intervention
hydrocortisone -X- _ I-Intervention
equivalent -X- _ O
dose -X- _ O
within -X- _ O
3 -X- _ O
days -X- _ O
after -X- _ O
ICU -X- _ O
admission -X- _ O
, -X- _ O
determined -X- _ O
by -X- _ O
a -X- _ O
sensitivity -X- _ O
analysis -X- _ O
) -X- _ O
on -X- _ O
hospital -X- _ O
mortality -X- _ O
( -X- _ O
the -X- _ O
primary -X- _ O
outcome -X- _ O
) -X- _ O
was -X- _ O
assessed -X- _ O
by -X- _ O
multivariable -X- _ O
logistic -X- _ O
regression -X- _ O
analysis -X- _ O
, -X- _ O
and -X- _ O
further -X- _ O
confirmed -X- _ O
in -X- _ O
a -X- _ O
propensity -X- _ O
score-matched -X- _ O
cohort. -X- _ O
RESULTS -X- _ O
: -X- _ O
Among -X- _ B-Outcome
the -X- _ I-Outcome
241 -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
influenza-associated -X- _ I-Outcome
ARDS -X- _ I-Outcome
, -X- _ I-Outcome
85 -X- _ I-Outcome
( -X- _ I-Outcome
35.3 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
patients -X- _ I-Outcome
receiving -X- _ I-Outcome
early -X- _ I-Outcome
corticosteroid -X- _ I-Outcome
treatment -X- _ I-Outcome
had -X- _ I-Outcome
similar -X- _ I-Outcome
baseline -X- _ I-Outcome
characteristics -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
a -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
hospital -X- _ I-Outcome
mortality -X- _ I-Outcome
rate -X- _ I-Outcome
than -X- _ I-Outcome
those -X- _ I-Outcome
without -X- _ I-Outcome
early -X- _ I-Outcome
corticosteroid -X- _ I-Outcome
treatment -X- _ I-Outcome
[ -X- _ I-Outcome
43.5 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
37 -X- _ I-Outcome
/ -X- _ I-Outcome
85 -X- _ I-Outcome
) -X- _ I-Outcome
vs. -X- _ I-Outcome
19.2 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
30 -X- _ I-Outcome
/ -X- _ I-Outcome
156 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.001 -X- _ I-Outcome
] -X- _ I-Outcome
. -X- _ I-Outcome
Early -X- _ I-Outcome
corticosteroid -X- _ I-Outcome
treatment -X- _ I-Outcome
was -X- _ I-Outcome
independently -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
increased -X- _ I-Outcome
hospital -X- _ I-Outcome
mortality -X- _ I-Outcome
in -X- _ I-Outcome
overall -X- _ I-Outcome
patients -X- _ I-Outcome
[ -X- _ I-Outcome
adjusted -X- _ I-Outcome
odds -X- _ I-Outcome
ratio -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
) -X- _ I-Outcome
= -X- _ I-Outcome
5.02 -X- _ I-Outcome
( -X- _ I-Outcome
2.39–10.54 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.001 -X- _ I-Outcome
] -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
subgroups. -X- _ I-Outcome
Earlier -X- _ I-Outcome
treatment -X- _ I-Outcome
and -X- _ I-Outcome
higher -X- _ I-Outcome
dosing -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
higher -X- _ I-Outcome
hospital -X- _ I-Outcome
mortality. -X- _ I-Outcome
Early -X- _ I-Outcome
corticosteroid -X- _ I-Outcome
treatment -X- _ I-Outcome
was -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
significantly -X- _ I-Outcome
increased -X- _ I-Outcome
odds -X- _ I-Outcome
of -X- _ I-Outcome
subsequent -X- _ I-Outcome
bacteremia -X- _ I-Outcome
[ -X- _ I-Outcome
adjusted -X- _ I-Outcome
odds -X- _ I-Outcome
ratio -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
) -X- _ I-Outcome
= -X- _ I-Outcome
2.37 -X- _ I-Outcome
( -X- _ I-Outcome
1.01–5.56 -X- _ I-Outcome
) -X- _ I-Outcome
] -X- _ I-Outcome
. -X- _ I-Outcome
The -X- _ I-Outcome
analyses -X- _ I-Outcome
using -X- _ I-Outcome
a -X- _ I-Outcome
propensity -X- _ I-Outcome
score-matched -X- _ I-Outcome
cohort -X- _ I-Outcome
showed -X- _ I-Outcome
consistent -X- _ I-Outcome
results. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Early -X- _ B-Outcome
corticosteroid -X- _ I-Outcome
treatment -X- _ I-Outcome
was -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
significantly -X- _ I-Outcome
increased -X- _ I-Outcome
hospital -X- _ I-Outcome
mortality -X- _ I-Outcome
in -X- _ I-Outcome
adult -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
influenza- -X- _ I-Outcome
associated -X- _ I-Outcome
ARDS. -X- _ I-Outcome
Earlier -X- _ I-Outcome
treatment -X- _ I-Outcome
and -X- _ I-Outcome
higher -X- _ I-Outcome
dosing -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
higher -X- _ I-Outcome
hospital -X- _ I-Outcome
mortality. -X- _ I-Outcome
Clinicians -X- _ O
should -X- _ O
be -X- _ O
cautious -X- _ O
while -X- _ O
using -X- _ O
corticosteroid -X- _ O
treatment -X- _ O
in -X- _ O
this -X- _ O
patient -X- _ O
group -X- _ O
. -X- _ O

